Glenmark Pharmaceuticals receives ANDA approval for Atovaquone Oral Suspension USP, 750 mg/5 mL
Deepthi | Myequity news | Date : 22-11-2018 10:30:00 IST
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Atovaquone Oral Suspension USP, 750 mg/5 mL, a generic version of Mepron®1 Oral Suspension, 750 mg/5 mL, of GlaxoSmithKline LLC.
According to IQVIATM sales data, the Mepron® Oral Suspension, 750 mg/5 mL market2 achieved annual sales of approximately $119.1 million*.
About Glenmark Pharmaceuticals:
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.